NEW YORK, March 3, 2011 (GLOBE NEWSWIRE) — Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it has selected inVentiv Clinical Solutions to manage its Phase III pivotal trial with Iferanserin and Almac Group to provide electronic patient-reported outcomes solutions.
inVentiv Clinical has supported 118 gastrointestinal studies [...] http://bit.ly/fhzUcI
No comments:
Post a Comment